Client News

Galimedix announces participation at fall 2026 investor, partnering, and scientific conferences

Newron presents H1 2026 results and provides corporate update

Formycon sets Benchmark in Biosimilar Development: Scientific Foundation of the innovative Development Program for FYB206 published in the Journal BioDrugs

Abivax Presents Business Updates and First Half 2026 Financial Result

InflaRx to Host Virtual Capital Markets Day

Galimedix establishes Scientific Advisory Board for Alzheimer’s disease to guide development of novel oral drug candidate, GAL-101

QuE-MRT Enters Its Next Phase: Progress in Quantum-Enhanced MRI in Germany

Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress

Mallia Aesthetics Presents Data on the Role of sCD83 in Hair Growth at Third Barcelona Hair Meeting

CorTec Receives Second FDA Breakthrough Device Designation for Brain Interchange™